Effectiveness of rituximab treatment in primary sjögren's syndrome: A randomized, double-blind, placebo-controlled trial

Arthritis and Rheumatism

Volumn 62, Issue 4, 2010, Pages 960-968

  Meijer, J M ^a   Meiners, P M ^a   Vissink, A ^a   Spijkervet, F K L ^a   Abdulahad, W ^a   Kamminga, N ^a   Brouwer, E ^a   Kallenberg, C G M ^a   Bootsma, H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CLEMASTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DYE; HYDROXYCHLOROQUINE; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB;

ADULT; ARTHRALGIA; ARTHRITIS; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLOW RATE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GENERAL ASPECTS OF DISEASE; HEALTH SURVEY; HERPES ZOSTER; HUMAN; LABORATORY; LACRIMAL GLAND; MALE; MYALGIA; OPPORTUNISTIC INFECTION; OTITIS MEDIA; PAROTID GLAND DISEASE; POLYNEUROPATHY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; RESPIRATORY TRACT INFECTION; RUBELLA; SALIVATION; SCORING SYSTEM; SERUM SICKNESS; SHORT FORM 36; SJOEGREN SYNDROME; TOXOPLASMOSIS; VASCULITIS; VIRUS INFECTION; VISUAL ANALOG SCALE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BLOOD CELL COUNT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; LACRIMAL APPARATUS; MALE; MIDDLE AGED; PLACEBOS; SALIVA; SJOGREN'S SYNDROME;

EID: 77950538947     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27314     Document Type: Article

References (26)

1. Meijer JM, Meiners PM, Huddleston Slater JJ, Spijkervet FK, Kallenberg CGM, Vissink A, et al. Health-related quality of life, employment and disability in patients with Sjögren's syndrome. Rheumatology (Oxford) 2009;48:1077-1082
2. Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007;57: 310-317
3. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52:2740-2750
4. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American - European Consensus Group. Ann Rheum Dis 2002;61:554-558
5. Pijpe J, Kalk WW, van der Wal JE, Vissink A, Kluin PM, Roodenburg JL, et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjögren's syndrome. Rheumatology (Oxford) 2007;46:335-341
6. Dawes C. Circadian rhythms in human salivary flow rate and composition. J Physiol 1972;220:529-545
7. Ferguson DB, Fort A, Elliott AL, Potts AJ. Circadian rhythms in human parotid saliva flow rate and composition. Arch Oral Biol 1973;18:1155-1173
8. Burlage FR, Pijpe J, Coppes RP, Hemels ME, Meertens H, Canrinus A, et al. Variability of flow rate when collecting stimulated human parotid saliva. Eur J of Oral Sci 2005;113:386-390
9. Kalk WW, Vissink A, Stegenga B, Bootsma H, Nieuw Amerongen AV, Kallenberg CG. Sialometry and sialochemistry: a non-invasive approach for diagnosing Sjögren's syndrome. Ann Rheum Dis 2002;61:137-144
10. Kalk WW, Vissink A, Spijkervet FK, Bootsma H, Kallenberg CG, Nieuw Amerongen AV. Sialometry and sialochemistry: diagnostic tools for Sjögren's syndrome. Ann Rheum Dis 2001;60:1110-1116
11. Kalk WW, Mansour K, Vissink A, Spijkervet FK, Bootsma H, Kallenberg CG, et al. Oral and ocular manifestations in Sjögren's syndrome. J Rheumatol 2002;29:924-930
12. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI): psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-325
13. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483
14. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-2806
15. Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, et al, for the International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the dose-ranging assessment. J Rheumatol 2008;35:20-30.
16. Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 2007;46:626-630
17. Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-920
18. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, et al. Reduction of fatigue in Sjögren's syndrome with rituximab: results of a randomised, double-blind, placebo controlled pilot study. Ann Rheum Dis 2008;67:1541-1544
19. Miyawaki S, Nishiyama S, Matoba K. Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome. Intern Med 1999;38:938-943
20. Fox PC, Datiles M, Atkinson JC, Macynski AA, Scott J, Fletcher D, et al. Prednisone and piroxicam for treatment of primary Sjögren's syndrome. Clin Exp Rheumatol 1993;11:149-156
21. Pijpe J, Kalk WW, Bootsma H, Spijkervet FK, Kallenberg CG, Vissink A. Progression of salivary gland dysfunction in patients with Sjögren's syndrome. Ann Rheum Dis 2007;66:107-112
22. Fleischmann RM. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum 2009;38:265-280
23. Gurcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009;9:10-25.
24. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-3908
25. Meijer JM, Pijpe J, Bootsma H, Vissink A, Kallenberg CG. The future of biologic agents in the treatment of Sjögren's syndrome. Clin Rev Allergy Immunol 2007;32:292-297
26. Meijer JM, Pijpe J, Vissink A, Kallenberg CG, Bootsma H. Treatment of primary Sjögren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 2009;68:284-285